Clinical trials: Autoimmune Disorder
Type 1 Diabetes, Type 2 Diabetes
The Set-Point Study: Evaluating Effects of Changing Glucose Target on Bionic Pancreas Performance
The current study is designed to determine the effect on mean glucose, hypoglycemia, glucagon usage, and insulin usage of adjusting upward the glucose target of the bi-hormonal bionic pancreas, and determine whether there is a…
- Trial name
- NCT02509065
- Testing
- Bionic Pancreas, Usual Care
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Massachusetts General Hospital
Hemophilia A
Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Acquired Hemophilia A
The purpose of this study is to evaluate the rate of response when administering rituximab to suppress or eliminate the anti-body in a patient's blood that inhibits the effectiveness of their factor replacement product compared…
- Trial name
- NCT00306670
- Testing
- Rituxan, prednisone
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Georgetown University
Chronic Plaque Psoriasis
Phase II Efficacy Study Looking at a Single-dose of One of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type Psoriasis
This is an exploratory, 4 arm, parallel group, placebo-controlled study comparing three doses of AIN457 to placebo. Subjects with a diagnosis of moderate to severe chronic plaque psoriasis will be randomized to receive either…
- Trial name
- NCT00770965
- Testing
- AIN457
- Where
- 5 sites in United States
- Volunteers
- 80 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Duloxetine for Multiple Sclerosis Pain
This study is designed to primarily assess the efficacy and safety of duloxetine 60-120 mg once daily (QD) compared with placebo on the reduction of pain severity in participants with central neuropathic pain due to Multiple…
- Trial name
- NCT00755807
- Testing
- Duloxetine Hydrochloride (HCI)
- Where
- 22 sites in United States, Belgium and 2 more
- Volunteers
- 239 people
- Sponsor
- Eli Lilly and Company
Multiple Sclerosis
Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multiple Sclerosis
Multiple sclerosis is the most common inflammatory disease of the central nervous system and a common cause of disability in young adults.
- Trial name
- NCT04767698
- Testing
- Belimumab, Short-course Ocrelizumab, Continued Ocrelizumab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Johns Hopkins University
Diabetes Mellitus, Type 1, Type 1 Diabetes
Feasibility of Closed-loop Automated Insulin Delivery System by Primary Care & Endocrinology, in Person & Via Telehealth
This is a study assessing the feasibility of using the insulin-only configuration of the iLet bionic pancreas with initiation in pump-naïve people with type 1 diabetes in a primary care practice with either in-person training and…
- Conditions
- Diabetes Mellitus, Type 1, Type 1 Diabetes, Diabetes, Autoimmune, Diabetes type1
- Trial name
- NCT05168657
- Testing
- Bionic Pancreas, Usual Care
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- University of Colorado, Denver
Neurological Disorder, Autoimmune Diseases
Disease-Modifying Treatments for Myasthenia Gravis
This study is designed to address the evidence gaps in a real-world setting and help patients with MG choose treatments that are best suited to them.
- Trial name
- PROMISE-MG (NCT03490539)
- Testing
- Mycophenolate Mofetil, Azathioprine
- Where
- 19 sites in United States, Canada
- Volunteers
- 82 people
- Sponsor
- Duke University
Rheumatoid Arthritis
A Long-Term Extension Study of WA19926 on the Safety of Tocilizumab (RoActemra/Actemra) in Participants With Early Moderate to Severe Rheumatoid Arthritis
This open-label, single arm, multicenter long-term extension study will evaluate the safety and efficacy of tocilizumab (RoActemra/Actemra) in participants with moderate to severe rheumatoid arthritis who have completed the…
- Trial name
- NCT01655381
- Testing
- Tocilizumab
- Where
- 6 sites in France
- Volunteers
- 15 people
- Sponsor
- Hoffmann-La Roche
Lupus Nephritis
An Exploratory Maintenance Trial of BI 655064 in Patients With Lupus Nephritis
The main objectives of this trial are to evaluate the long term efficacy and safety of different doses of BI 655064 versus placebo as add-on therapy to Standard of Care (SOC) during maintenance therapy for lupus nephritis.
- Trial name
- NCT03385564
- Testing
- BI 655064
- Where
- 36 sites in United States, Australia and 14 more
- Volunteers
- 69 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 1
Development of a Behavioral Observer for Type 1 Diabetes Mellitus
Development of a bio-behavioral stochastic model-predictive controller (SMPC) for use as an artificial pancreas in T1DM requires fundamental behavioral and physiology studies, as well as translational modeling and engineering…
- Trial name
- Phase1 (NCT01434030)
- Testing
- Focus Group
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- University of Virginia
Lupus Nephritis
Aurinia Renal Response in Active Lupus With Voclosporin
The purpose of this study is to assess the efficacy of voclosporin compared with placebo in achieving renal response after 52 weeks of therapy in subjects with active lupus nephritis.
- Trial name
- AURORA (NCT03021499)
- Testing
- Voclosporin
- Where
- 185 sites in United States, Argentina and 29 more
- Volunteers
- 358 people
- Sponsor
- Aurinia Pharmaceuticals Inc.
Generalized Myasthenia Gravis
Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis
The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab for the treatment of participants with generalized myasthenia gravis (gMG).
- Trial name
- NCT03920293
- Testing
- Ravulizumab
- Where
- 106 sites in United States, Austria and 13 more
- Volunteers
- 175 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Multiple Sclerosis
Stem Cells in Rapidly Evolving Active Multiple Sclerosis
This is a randomised, double-blind crossover study to study the effect of intravenous treatment with autologous (derived from the individuals themselves) mesenchymal stem cells (MSCs) in patients with multiple sclerosis (MS).
- Trial name
- STREAMS (NCT01606215)
- Testing
- Mesenchymal stem cells
- Where
- United Kingdom
- Volunteers
- 21 people
- Sponsor
- Imperial College London
Multiple Sclerosis, Cognition
Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis
The primary aim is to collect data to determine the correct effect size on the primary outcome to aid in the design of a larger study: The primary outcome is to determine if lipoic acid and omega-3 fatty acids can improve…
- Trial name
- NCT02133664
- Testing
- lipoic acid and omega-3 fatty acids
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Oregon Health and Science University
Rheumatoid Arthritis
A Study to Assess the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid Arthritis
The purpose of the study is to evaluate the pharmacokinetics and safety of certolizumab pegol in adults with active rheumatoid arthritis.
- Trial name
- NCT04740814
- Testing
- Certolizumab pegol
- Where
- 14 sites in United States
- Volunteers
- 33 people
- Sponsor
- UCB Biopharma SRL
Sjogren's Syndrome
Assessment of Inflammatory Biomarkers Expressed in a Sjogren's Population: Effect of a Topical Steroid Intervention
The primary purpose of this study is to quantify the change in expression of biomarkers on the ocular surface of Sjogren's Syndrome participants after treatment with Maxidex.
- Trial name
- NCT00631358
- Testing
- Maxidex, No treatment
- Where
- 2 sites in Canada
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Alcon Research
Multiple Sclerosis
Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
The primary objective is to determine whether prolonged-release fampridine (10 mg twice daily) has a clinically meaningful effect on participant-reported walking ability over a 24-week study period.
- Trial name
- ENHANCE (NCT02219932)
- Testing
- fampridine
- Where
- 87 sites in United States, Bulgaria and 9 more
- Volunteers
- 646 people
- Sponsor
- Biogen
Rheumatoid Arthritis
Low-dose Recombinant Human IL-2 for the Treatment of Rheumatoid Arthritis
Rheumatoid arthritis (RA) is an immune-mediated inflammatory disease, characterized by symmetric poly-arthritis usually involving the small joints of the hands and feet.
- Trial name
- NCT02467504
- Testing
- hrIL-2 active, MTX, Folic Acid
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Peking University People's Hospital
Systemic Lupus Erythematosus
Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE)
Background: Lupus causes a person s immune system to attack the body. It can cause blood vessel problems, heart attack, or stroke. Researchers want to see if the drug pioglitazone may help.
- Trial name
- NCT02338999
- Testing
- PET/CT, Pioglitazone
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type I Diabetes Mellitus
Glutamine and Insulin Sensitivity in Type I Diabetes
Insulin is crucial to help the body metabolize ('burn') sugar (glucose). Even though juvenile (type 1) diabetes (T1D) is primarily due to the lack of insulin, patients with T1D tend to become less sensitive to insulin…
- Trial name
- NCT01467063
- Testing
- Glutamine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Nemours Children's Clinic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.